Scienture launches REZENOPY, cites patent wins and payer gains in Q2 2026 update

Scienture Holdings, Inc. (NASDAQ: SCNX) said on August 14, 2026 that it commenced the commercial launch of REZENOPY™ and began fulfillment of initial purchase orders, marking an important milestone in the company's commercialization strategy.¹ Executive Chairman and co-CEO Shankar Hariharan said the company is expanding payer access and commercial availability for Arbli™ while simultaneously bringing REZENOPY™ online commercially in the third quarter of 2026.¹

On intellectual property, the United States Patent and Trademark Office granted a second patent covering REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg, extending protection for the product through 2041.¹ The USPTO also granted a third patent covering Arbli™ (losartan potassium) oral suspension, extending expected market exclusivity through 2041.¹

On payer access, Scienture secured formulary coverage for REZENOPY™ with a large national health plan and expanded its commercial team to support market penetration and growth.¹ It also expanded ARBLI™ payer coverage and commercial access, adding approximately 12.5 million covered lives.¹

Financially, the company reported revenue that increased approximately 510% sequentially to $343,639 in Q2 2026, compared with $56,325 in Q1 2026.¹ As of June 30, 2026, the company had cash, cash equivalents and restricted cash of approximately $11.2 million compared to approximately $6.7 million of cash and cash equivalents as of December 31, 2025.¹

President and co-CEO Narasimhan Mani said the results left the company with a stronger financial position as it executes the next phase of its commercial growth strategy, and that it believes it is on the right path to deliver business growth in coming quarters.¹